Pfizer/BioNTech Start Phase 2 Trial For COVID-19 Vaccine Against Omicron Subvariant

 

• Pfizer Inc 
  PFE-0.66%+ Free Alerts
   and BioNTech SE 
  BNTX-2.40%+ Free Alerts
   initiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. 
• This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant. 
• The enhanced spike protein encoded from the mRNAs in BNT162b5 has been modified to increase the magnitude and breadth of the immune response that could better protect against COVID-19. 
• The companies plan to evaluate this as the first of multiple vaccine candidates with an enhanced design.
• BNT162b5 will be evaluated in a U.S.-based study enrolling approximately 200 participants aged between 18 and 55 who have received one booster dose of a U.S.-authorized COVID-19 vaccine at least 90 days before their first study visit. 

https://www.benzinga.com/general/biotech/22/07/28230678/pfizerbiontech-start-ohase-2-trial-for-covid-19-vaccine-against-omicron-subvariant